Sonoma Pharmaceuticals (SNOA) Other Accumulated Expenses (2015 - 2026)

Sonoma Pharmaceuticals' Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $533000.0 for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 9.45% year-over-year to $533000.0 in Q1 2026; TTM through Mar 2026 was $533000.0, a 9.45% increase from a year earlier, with the FY2026 full-year figure at $533000.0, up 9.45% from the prior year.
• Other Accumulated Expenses advanced to $533000.0 in Q1 2026 per SNOA's latest filing, from $487000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $784000.0 in Q1 2022 and bottomed at $487000.0 in Q1 2025.
• The 5-year median for Other Accumulated Expenses is $566000.0 (2023), against an average of $612800.0.
• Across the five-year window, Other Accumulated Expenses surged 113.62% in 2022 and dropped 29.83% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $784000.0 in 2022, then decreased by 27.81% to $566000.0 in 2023, then rose by 22.61% to $694000.0 in 2024, then fell by 29.83% to $487000.0 in 2025, then rose by 9.45% to $533000.0 in 2026.
• Per Business Quant, the three latest SNOA Other Accumulated Expenses figures stand at $533000.0 (Q1 2026), $487000.0 (Q1 2025), and $694000.0 (Q1 2024).